• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经胶质瘤干细胞重塑胶质母细胞瘤中的免疫耐受微环境,并与治疗进展相关。

Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements.

机构信息

Department of Neurosurgery, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, Jiangsu, China.

Department of Neurosurgery, The Affiliated Suzhou Science and Technology Town Hospital of Nanjing University Medical School, Suzhou, Jiangsu, China.

出版信息

Cancer Biomark. 2024;41(1):1-24. doi: 10.3233/CBM-230486.

DOI:10.3233/CBM-230486
PMID:39240627
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11492047/
Abstract

Glioma is the most common primary tumor of the central nervous system (CNS). Glioblastoma (GBM) is incurable with current treatment strategies. Additionally, the treatment of recurrent GBM (rGBM) is often referred to as terminal treatment, necessitating hospice-level care and management. The presence of the blood-brain barrier (BBB) gives GBM a more challenging or "cold" tumor microenvironment (TME) than that of other cancers and gloma stem cells (GSCs) play an important role in the TME remodeling, occurrence, development and recurrence of giloma. In this review, our primary focus will be on discussing the following topics: niche-associated GSCs and macrophages, new theories regarding GSC and TME involving pyroptosis and ferroptosis in GBM, metabolic adaptations of GSCs, the influence of the cold environment in GBM on immunotherapy, potential strategies to transform the cold GBM TME into a hot one, and the advancement of GBM immunotherapy and GBM models.

摘要

脑胶质瘤是中枢神经系统(CNS)最常见的原发性肿瘤。目前的治疗策略无法治愈胶质母细胞瘤(GBM)。此外,复发性 GBM(rGBM)的治疗通常被称为终末期治疗,需要临终关怀护理和管理。血脑屏障(BBB)的存在使 GBM 比其他癌症具有更具挑战性或“冷”的肿瘤微环境(TME),而胶质母细胞瘤干细胞(GSCs)在 TME 重塑、发生、发展和复发性胶质母细胞瘤中发挥重要作用。在这篇综述中,我们将主要讨论以下主题:与龛相关的 GSCs 和巨噬细胞,涉及 GBM 中细胞焦亡和铁死亡的 GSC 和 TME 的新理论,GSCs 的代谢适应,冷环境对 GBM 免疫治疗的影响,将冷 GBM TME 转化为热 TME 的潜在策略,以及 GBM 免疫治疗和 GBM 模型的进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a8/11492047/cb422e0dd23f/cbm-41-cbm230486-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a8/11492047/ef8ed457b7b6/cbm-41-cbm230486-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a8/11492047/431525cb1d5c/cbm-41-cbm230486-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a8/11492047/cb422e0dd23f/cbm-41-cbm230486-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a8/11492047/ef8ed457b7b6/cbm-41-cbm230486-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a8/11492047/431525cb1d5c/cbm-41-cbm230486-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a8/11492047/cb422e0dd23f/cbm-41-cbm230486-g003.jpg

相似文献

1
Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements.神经胶质瘤干细胞重塑胶质母细胞瘤中的免疫耐受微环境,并与治疗进展相关。
Cancer Biomark. 2024;41(1):1-24. doi: 10.3233/CBM-230486.
2
Oncolytic virotherapy improves immunotherapies targeting cancer stemness in glioblastoma.溶瘤病毒疗法改善了针对胶质母细胞瘤肿瘤干性的免疫疗法。
Biochim Biophys Acta Gen Subj. 2024 Sep;1868(9):130662. doi: 10.1016/j.bbagen.2024.130662. Epub 2024 Jun 18.
3
Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.溶瘤病毒疗法在胶质母细胞瘤患者中诱导肿瘤巨噬细胞表型转变,导致胶质母细胞瘤微环境改变。
Neuro Oncol. 2018 Oct 9;20(11):1494-1504. doi: 10.1093/neuonc/noy082.
4
Elevated α-1,2-mannosidase MAN1C1 in glioma stem cells and its implications for immunological changes and prognosis in glioma patients.脑胶质瘤干细胞中 α-1,2-甘露糖苷酶 MAN1C1 的上调及其对脑胶质瘤患者免疫变化和预后的影响。
Sci Rep. 2024 Sep 27;14(1):22159. doi: 10.1038/s41598-024-72901-2.
5
Immunotherapy targeting glioma stem cells--insights and perspectives.针对神经胶质瘤干细胞的免疫疗法——见解与展望。
Expert Opin Biol Ther. 2012 Feb;12(2):165-78. doi: 10.1517/14712598.2012.648180. Epub 2011 Dec 26.
6
The dual role of POSTN in maintaining glioblastoma stem cells and the immunosuppressive phenotype of microglia in glioblastoma.POSTN 在维持胶质母细胞瘤干细胞和小胶质细胞免疫抑制表型中的双重作用。
J Exp Clin Cancer Res. 2024 Sep 4;43(1):252. doi: 10.1186/s13046-024-03175-9.
7
Image-based assessment of natural killer cell activity against glioblastoma stem cells.基于图像的自然杀伤细胞对神经胶质瘤干细胞活性的评估。
FEBS Open Bio. 2024 Jun;14(6):1028-1034. doi: 10.1002/2211-5463.13818. Epub 2024 May 13.
8
Multiple Synergistic Effects of the Microglia Membrane-Bionic Nanoplatform on Mediate Tumor Microenvironment Remodeling to Amplify Glioblastoma Immunotherapy.基于小胶质细胞膜仿生纳米平台的多重协同作用调控肿瘤微环境重塑以增强胶质母细胞瘤免疫治疗
ACS Nano. 2024 Jun 4;18(22):14469-14486. doi: 10.1021/acsnano.4c01253. Epub 2024 May 21.
9
Machine Learning-Directed Conversion of Glioblastoma Cells to Dendritic Cell-Like Antigen-Presenting Cells as Cancer Immunotherapy.机器学习引导的胶质母细胞瘤细胞向树突状细胞样抗原呈递细胞的转化作为癌症免疫疗法
Cancer Immunol Res. 2024 Oct 1;12(10):1340-1360. doi: 10.1158/2326-6066.CIR-23-0721.
10
Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.脑胶质瘤肿瘤微环境中的缺氧:新型治疗方法的主要破坏者。
Front Immunol. 2024 Jun 26;15:1384249. doi: 10.3389/fimmu.2024.1384249. eCollection 2024.

引用本文的文献

1
Physical activity and glioblastoma: a paradigm shift in neuro-oncology therapy.体育活动与胶质母细胞瘤:神经肿瘤学治疗的范式转变
Front Oncol. 2025 Jul 30;15:1638060. doi: 10.3389/fonc.2025.1638060. eCollection 2025.
2
Overcoming barriers in glioblastoma: The potential of CAR T cell immunotherapy.克服胶质母细胞瘤中的障碍:嵌合抗原受体T细胞免疫疗法的潜力。
Theranostics. 2025 Jun 12;15(14):7090-7126. doi: 10.7150/thno.114257. eCollection 2025.
3
Molecular Profile as an Outcome Predictor in Glioblastoma along with MRI Features and Surgical Resection: A Scoping Review.

本文引用的文献

1
Understanding and Overcoming Immunosuppression Shaped by Cancer Stem Cells.理解并克服癌症干细胞所塑造的免疫抑制。
Cancer Res. 2023 Jul 5;83(13):2096-2104. doi: 10.1158/0008-5472.CAN-23-0230.
2
Abnormal glycosylation in glioma: related changes in biology, biomarkers and targeted therapy.胶质瘤中的异常糖基化:生物学、生物标志物及靶向治疗方面的相关变化
Biomark Res. 2023 May 26;11(1):54. doi: 10.1186/s40364-023-00491-8.
3
NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
胶质母细胞瘤的分子谱与 MRI 特征和手术切除的预后预测:范围综述。
Int J Mol Sci. 2024 Sep 8;25(17):9714. doi: 10.3390/ijms25179714.
NADPH 氧化酶亚基 CYBB 通过调节 Nrf2/SOD2 赋予间充质型胶质母细胞瘤对化疗和铁死亡的耐药性。
Int J Mol Sci. 2023 Apr 22;24(9):7706. doi: 10.3390/ijms24097706.
4
Mining glycosylation-related prognostic lncRNAs and constructing a prognostic model for overall survival prediction in glioma: A study based on bioinformatics analysis.基于生物信息学分析挖掘与胶质瘤患者总生存期相关的糖基化修饰预后长链非编码 RNA 并构建预后模型
Medicine (Baltimore). 2023 May 5;102(18):e33569. doi: 10.1097/MD.0000000000033569.
5
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.不断演变的肿瘤微环境:从癌症起始到转移灶生长
Cancer Cell. 2023 Mar 13;41(3):374-403. doi: 10.1016/j.ccell.2023.02.016.
6
Interaction of tumor-associated microglia/macrophages and cancer stem cells in glioma.肿瘤相关小胶质细胞/巨噬细胞与脑胶质瘤肿瘤干细胞的相互作用。
Life Sci. 2023 May 1;320:121558. doi: 10.1016/j.lfs.2023.121558. Epub 2023 Mar 7.
7
The "Superoncogene" Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme.《多形性胶质母细胞瘤中代谢与基因表达交汇的“超级癌基因”Myc》
Int J Mol Sci. 2023 Feb 20;24(4):4217. doi: 10.3390/ijms24044217.
8
Comprehensive Analysis Identified Glycosyltransferase Signature to Predict Glioma Prognosis and TAM Phenotype.全面分析鉴定糖基转移酶特征以预测胶质瘤预后和 TAM 表型。
Biomed Res Int. 2023 Jan 11;2023:6082635. doi: 10.1155/2023/6082635. eCollection 2023.
9
Glioblastoma stem cell HISTArionics.胶质母细胞瘤干细胞 HISTArionics。
Cell Stem Cell. 2022 Nov 3;29(11):1509-1510. doi: 10.1016/j.stem.2022.10.004.
10
From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology Modeling in Cancer Immunotherapy.从冷到热:定量系统药理学模型在癌症免疫治疗中的观念转变和未来机遇。
Clin Pharmacol Ther. 2023 May;113(5):963-972. doi: 10.1002/cpt.2770. Epub 2022 Nov 10.